At the news
? NEUTRALIMPACT 3/10 8-K filed Apr 15, 2026 at 06:05 ET
Structure Therapeutics appointed Matthew Lang as Chief Operating Officer and General Counsel, effective April 15, 2026. Lang brings extensive biopharmaceutical leadership experience from roles at Metsera, Lyell Immunopharma, and Myovant Sciences.
- Matthew Lang appointed as COO and General Counsel effective April 15, 2026
- Lang previously served as Chief Legal Officer at Metsera and held executive roles at Lyell Immunopharma and Myovant Sciences
- Compensation package includes $560,000 base salary, annual bonus target of 40%, and equity grants totaling 454,545 ordinary shares (151,515 ADSs)
- Equity awards consist of stock options for 223,776 shares, time-based RSUs for 184,614 shares, and performance-based RSUs for 46,155 shares
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access